Hence treatment with PBT was recommended. Treatment planning was guided by measurement of tumour dimensions using ultrasonography.
Comment
The standard treatment for OSSN is surgical excision with safety margin and cryotherapy to the edges. 1 MMC, 5-fluorouracil, interferon, 2 and radiotherapy (including external beam radiotherapy and brachytherapy) 3 have been used as adjuvant treatment with variable success rates.
PBT, a type of external beam radiotherapy, delivers a high dose of ionizing radiation to the tumour with minimal damage to surrounding tissues. It has been used successfully to treat head and neck SCCs, 4 carcinomas elsewhere, 5 as well as other ocular tumours (mainly choroidal melanoma). 6 Only one case is reported in the literature for which PBT was successfully used as primary treatment for invasive OSSN 7 and we report the first two successful cases in United Kingdom. A case series in which PBT was used for recurrent OSSN or where the surgical margins were involved after excision was published with encouraging results. 8 In both presented cases, PBT has regressed the tumour without recurrence. Both patients received a 6-week course of topical steroids post treatment. No immediate side effects were noted, however one developed a cataract 2 years later, and the second developed a patch of scleral thinning that was stable on follow-up. We suspect it was an area of deeper tumour invasion that melted away with treatment ( Figure 1g) .
We believe that PBT should be considered for OSSN when surgical excision is not possible.
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The authors declare no conflict of interest. Current trends in the NHS include increased productivity and greater clinic subspecialisation while also being committed to ensuring high-quality patientcentred care. 1 Patients are more likely to be happy with their care if they are satisfied with waiting times, being more likely to comply with advice, improving health outcomes. 2 With current drives to increase efficiency and subspecialisation of ophthalmology out-patient clinics, there are pressures to define a standard number of patients seen per session. Should it be assumed that the same number of patients can be seen across different subspecialties?
We prospectively assessed appointment duration for 364 consecutive patients (44.8% new referrals) seen by a single doctor (HB) over a 2-month period in a district general hospital setting. We compared the appointment type (new vs follow-up) and four subspecialities: glaucoma, adult general (including post-operative cataracts), paediatric, and adult motility (including neuro-ophthalmology). The face-to-face patient contact time was measured to the nearest second. Results are expressed in minutes as Mean±SD. Appointment type was compared using a paired two-tailed t-test and subspecialties were compared using ANOVA. The level of significance was taken as Po0.05.
Results are summarised in Table 1 . There was a statistically significant difference in appointment duration between new and follow-up appointments (t ¼ 2.64, Po0.01) and between adult motility patients compared with the other three subspecialties (Po0.01). When new appointments were compared by subspecialty, adult motility appointments were statistically longer than paediatric and adult general visits (Po0.05). Also, for follow-up appointments, there was a statistical difference between adult glaucoma and adult motility patients (Po0.05).
These data indicate that the mean appointment time does differ between type and subspecialty. There were limitations of our study including the single-doctor nature of the assessment, smaller number of patients seen in certain groups, the limited number of subspecialties, and non-inclusion of time required to scan the notes or dictate letters.
We conclude that appointment duration in the eye clinic is not the same across different ophthalmic subspecialties and should be considered in any outpatient service reconfiguration to ensure the continued quality and safety of patient care.
Sir, Severe bilateral anterior uveitis secondary to giardiasis, initially misdiagnosed as a side effect of metronidazole Giardiasis is a common worldwide cause of gastroenteritis. We report a case complicated by severe bilateral anterior uveitis, discussing possible mechanisms of ocular involvement.
Case report
A 57-year-old Caucasian female presented with painful visual loss in her left eye. Two weeks previously, she had developed diarrhoea and abdominal pain after returning from India. Microscopy of a stool sample demonstrated cysts of Giardia lamblia, but no evidence of Shigella spp, Campylobacter spp, Salmonella spp, or Escherichia coli spp. There was no past ophthalmic or other medical history. Oral metronidazole (400 mg t.i.d) was commenced by her general practitioner, but abandoned after she developed blurred vision which was presumed to be a side effect. However, ocular symptoms progressed despite cessation of the drug.
Visual acuity was 6/5 OD, 'count fingers' OS. There was marked AC activity with posterior synechiae, but no fibrin, hypopyon, or iris nodules. Vitritis obscured fundal details and rendered OCT imaging poor, but there was no evidence of cystoid macular oedema or vasculitis. The fellow eye was normal. Other than gastrointestinal upset, there were no systemic features-specifically no rash, arthritis, or conjunctivitis. Acute anterior uveitis was diagnosed and treated with hourly g. dexamethasone and g. cyclopentolate t.i.d. Oral metronidazole was restarted.
Four days later, after the patient had again stopped taking the metronidazole-still concerned it was causing 
